Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments (2014 - 2023)

Esperion Therapeutics has reported Change in Acquisitions & Divestments for 9 years, with the latest figure at $17.5 million in Q2 2023.

• For the quarter ending Q2 2023, Change in Acquisitions & Divestments rose 250.0% year-over-year to $17.5 million; the trailing twelve-month figure through Mar 2024 stood at $17.5 million (down 81.18% YoY), and the FY2023 full-year result was $42.5 million, down 37.5% from the prior year.
• Change in Acquisitions & Divestments for Q2 2023 stood at $17.5 million, down from $25.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $45.9 million in Q1 2019, with the low at $2.2 million in Q3 2020.
• Historically, Change in Acquisitions & Divestments has averaged $20.8 million across 4 years, with a median of $23.3 million in 2019.
• Annual changes were most pronounced in 2020 — Change in Acquisitions & Divestments sank 89.62% — and 2023, when it jumped 250.0%.
• Esperion Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2019, then sank by 55.0% to $2.2 million in 2020, then surged by 1233.38% to $30.0 million in 2022, then tumbled by 41.67% to $17.5 million in 2023.
• The last three Change in Acquisitions & Divestments figures came in at $17.5 million (Q2 2023), $25.0 million (Q1 2023), and $30.0 million (Q4 2022), per Business Quant data.